X

Quality Statement

Pacific Biosciences is committed to providing high-quality products that meet customer expectations and comply with regulations. We will achieve these goals by adhering to and maintaining an effective quality-management system designed to ensure product quality, performance, and safety.

X

Image Use Agreement

By downloading, copying, or making any use of the images located on this website (“Site”) you acknowledge that you have read and understand, and agree to, the terms of this Image Usage Agreement, as well as the terms provided on the Legal Notices webpage, which together govern your use of the images as provided below. If you do not agree to such terms, do not download, copy or use the images in any way, unless you have written permission signed by an authorized Pacific Biosciences representative.

Subject to the terms of this Agreement and the terms provided on the Legal Notices webpage (to the extent they do not conflict with the terms of this Agreement), you may use the images on the Site solely for (a) editorial use by press and/or industry analysts, (b) in connection with a normal, peer-reviewed, scientific publication, book or presentation, or the like. You may not alter or modify any image, in whole or in part, for any reason. You may not use any image in a manner that misrepresents the associated Pacific Biosciences product, service or technology or any associated characteristics, data, or properties thereof. You also may not use any image in a manner that denotes some representation or warranty (express, implied or statutory) from Pacific Biosciences of the product, service or technology. The rights granted by this Agreement are personal to you and are not transferable by you to another party.

You, and not Pacific Biosciences, are responsible for your use of the images. You acknowledge and agree that any misuse of the images or breach of this Agreement will cause Pacific Biosciences irreparable harm. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. You must include any copyright notice originally included with the images on all copies.

IMAGES ARE PROVIDED BY Pacific Biosciences ON AN "AS-IS" BASIS. Pacific Biosciences DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, BUT NOT LIMITED TO, NON-INFRINGEMENT, OWNERSHIP, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. IN NO EVENT SHALL Pacific Biosciences BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OF ANY KIND WHATSOEVER WITH RESPECT TO THE IMAGES.

You agree that Pacific Biosciences may terminate your access to and use of the images located on the PacificBiosciences.com website at any time and without prior notice, if it considers you to have violated any of the terms of this Image Use Agreement. You agree to indemnify, defend and hold harmless Pacific Biosciences, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Site from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of the terms of this Image Use Agreement or Pacific Biosciences' termination of your access to or use of the Site. Termination will not affect Pacific Biosciences' rights or your obligations which accrued before the termination.

I have read and understand, and agree to, the Image Usage Agreement.

I disagree and would like to return to the Pacific Biosciences home page.

Pacific Biosciences
Contact:

Authors: Osoegawa, Kazutoyo and Vayntrub, Tamara A and Wenda, Sabine and De Santis, Dianne and Barsakis, Konstantinos and Ivanova, Milena and Hsu, Susan and Barone, Jonathan and Holdsworth, Rhonda and Diviney, Mary and Askar, Medhat and Willis, Amanda and Railton, Dawn and Laflin, Sophie and Gendzekhadze, Ketevan and Oki, Arisa and Sacchi, Nicoletta and Mazzocco, Michela and Andreani, Marco and Ameen, Reem and Stavropoulos-Giokas, Catherine and Dinou, Amalia and Torres, Margareth and Dos Santos Francisco, Rodrigo and Serra-Pages, Carles and Goodridge, Damian and Balladares, Sandra and Bettinotti, Maria P and Iglehart, Brian and Kashi, Zahra and Martin, Russell and Saw, Chee Loong and Ragoussis, Jiannis and Downing, Jonathan and Navarrete, Cristina and Chong, Winnie and Saito, Katsuyuki and Petrek, Martin and Tokic, Stana and Padros, Karin and Beatriz Rodriguez, Ma and Zakharova, Viktoria and Shragina, Olga and Marino, Susana R and Brown, Nicholas K and Shiina, Takashi and Suzuki, Shingo and Spierings, Eric and Zhang, Qiuheng and Yin, Yuxin and Morris, Gerald P and Hernandez, Ana and Ruiz, Phillip and Khor, Seik-Soon and Tokunaga, Katsushi and Geretz, Aviva and Thomas, Rasmi and Yamamoto, Fumiko and Mallempati, Kalyan C and Gangavarapu, Sridevi and Kanga, Uma and Tyagi, Shweta and Marsh, Steven G E and Bultitude, Will P and Liu, Xiangjun and Cao, Dajiang and Penning, Maarten and Hurley, Carolyn K and Cesbron, Anne and Mueller, Claudia and Mytilineos, Joannis and Weimer, Eric T and Bengtsson, Mats and Fischer, Gottfried and Hansen, John A and Chang, Chia-Jung and Mack, Steven J and Creary, Lisa E and Fernandez-Viña, Marcelo A

The 17th International HLA and Immunogenetics Workshop (IHIW) organizers conducted a Pilot Study (PS) in which 13 laboratories (15 groups) participated to assess the performance of the various sequencing library preparation protocols, NGS platforms and software in use prior to the workshop. The organizers sent 50 cell lines to each of the 15 groups, scored the 15 independently generated sets of NGS HLA genotyping data, and generated "consensus" HLA genotypes for each of the 50 cell lines. Proficiency Testing (PT) was subsequently organized using four sets of 24 cell lines, selected from 48 of 50 PS cell lines, to validate the quality of NGS HLA typing data from the 34 participating IHIW laboratories. Completion of the PT program with a minimum score of 95% concordance at the HLA-A, HLA-B, HLA-C, HLA-DRB1 and HLA-DQB1 loci satisfied the requirements to submit NGS HLA typing data for the 17th IHIW projects. Together, these PS and PT efforts constituted the 17th IHIW Quality Control project. Overall PT concordance rates for HLA-A, HLA-B, HLA-C, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRB1, HLA-DRB3, HLA-DRB4 and HLA-DRB5 were 98.1%, 97.0% and 98.1%, 99.0%, 98.6%, 98.8%, 97.6%, 96.0%, 99.1%, 90.0% and 91.7%, respectively. Across all loci, the majority of the discordance was due to allele dropout. The high cost of NGS HLA genotyping per experiment likely prevented the retyping of initially failed HLA loci. Despite the high HLA genotype concordance rates of the software, there remains room for improvement in the assembly of more accurate consensus DNA sequences by NGS HLA genotyping software. Copyright © 2019 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Journal: Human immunology
DOI: 10.1016/j.humimm.2019.01.009
Year: 2019

Read Publication

 

Stay
Current

Visit our blog »